1. Home
  2. PSO vs ALGN Comparison

PSO vs ALGN Comparison

Compare PSO & ALGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pearson Plc

PSO

Pearson Plc

N/A

Current Price

$17.24

Market Cap

9.8B

ML Signal

N/A

Logo Align Technology Inc.

ALGN

Align Technology Inc.

N/A

Current Price

$163.41

Market Cap

10.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PSO
ALGN
Founded
1844
1997
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Books
Industrial Specialties
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.8B
10.5B
IPO Year
2000
2000

Fundamental Metrics

Financial Performance
Metric
PSO
ALGN
Price
$17.24
$163.41
Analyst Decision
Sell
Buy
Analyst Count
2
16
Target Price
$16.15
★ $186.50
AVG Volume (30 Days)
804.5K
★ 1.0M
Earning Date
02-25-2027
10-28-2026
Dividend Yield
★ 1.98%
N/A
EPS Growth
N/A
★ 0.53
EPS
N/A
★ 4.98
Revenue
N/A
★ $387,126,000.00
Revenue This Year
$4.10
$2.24
Revenue Next Year
$5.36
$3.04
P/E Ratio
★ $14.05
$33.11
Revenue Growth
N/A
★ 23.95
52 Week Low
$12.02
$130.23
52 Week High
$18.43
$200.44

Technical Indicators

Market Signals
Indicator
PSO
ALGN
Relative Strength Index (RSI) 48.34 63.09
Support Level $15.80 $151.31
Resistance Level $17.70 $182.05
Average True Range (ATR) 0.29 5.51
MACD -0.12 1.49
Stochastic Oscillator 16.55 85.30

Price Performance

Historical Comparison
PSO
ALGN

About PSO Pearson Plc

UK-listed Pearson is a testing and educational provider. Pearson's primary operations are in assessment and qualifications, testing and higher education, but they also provide English education and testing, virtual learning, prehiring testing and screening, and upskilling/reskilling. The company divested noncore businesses, including the Financial Times, The Economist, and the publishing house Penguin, and is now focused on serving as an educational resource and testing provider.

About ALGN Align Technology Inc.

Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.

Share on Social Networks: